Immunotherapy targeting amyloid-β showed promise for treatment of Alzheimer disease (AD) in preclinical studies, but trials in humans have yielded disappointing results. In their Perspectives article, Liu and colleagues discuss adverse effects of amyloid-targeted therapies, which have limited treatment efficacy, and propose strategies to optimize the design of future therapeutic antibodies for AD.
- Yu-Hui Liu
- Brian Giunta
- Yan-Jiang Wang